William Wallace: Hidden Vitamin B12 Deficiency and Better Testing Methods
William Wallace, Co-Founder and Chief Scientific Officer at Supplement Success Solutions, shared a post on X about a recent article by Ralph Carme, published in The American Journal of Clinical Nutrition, adding:
“Your B12 test measures two things and cannot distinguish between them.
Seventy to eighty percent of circulating vitamin B12 is bound to haptocorrin. The liver clears this fraction, and it never reaches the cells.
Twenty to thirty percent is bound to transcobalamin. This is the biologically active fraction that is actually delivered to tissues.
Clinicians refer to it as holo transcobalamin.
Standard serum vitamin B12 tests add both fractions together. A result that appears ‘normal’ can still mask a cellular deficiency, and these
tests miss approximately twenty-five to thirty percent of true deficiency cases.
The better tests are:
- Holo transcobalamin, which directly measures the active fraction
- Methylmalonic acid, which rises only when cellular vitamin B12 is truly insufficient and is considered a functional gold standard
- Homocysteine, which also rises in deficiency but is less specific because it can also increase with low folate, low vitamin B6, mthfr variants, kidney issues, aging. Less specific.
Who should care: adults over sixty years of age, long-term metformin users (ten to thirty percent develop deficiency), proton
pump inhibitor users, vegetarians and vegans, and anyone with unexplained fatigue, neuropathy, cognitive changes, or macrocytic anemia.
If vitamin B12 is reported as normal but symptoms do not match, it is reasonable to request holo transcobalamin and methylmalonic acid
testing.”
Title: Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II
Authors: Ralph Carme

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support